pharmaphorum July 4, 2024
A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim’s challenge to Medicare’s drug price negotiation programme, rejecting the company’s position.
Judge Michael Shea denied all of Boehringer’s claims that the Medicare negotiation programme the key policy in President Biden’s flagship Inflation Reduction Act, is unconstitutional.
In his order, Judge Shea said that Boehringer’s participation in Medicare is voluntary, albeit with “considerable economic incentive,” adding that the federal government is entitled to place conditions on companies who benefit from its programmes.
The verdict continues a run of setbacks for the pharma industry in its efforts to fight the programme, coming after defeats in court for Bristol-Myers Squibb and Johnson & Johnson,...
Today's Sponsors
Today's Sponsor